XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

Ethics Channel
subscribe to Ethics newsletter

Special Topics : Ethics

   DISCUSS   |   EMAIL   |   PRINT
Phase I cancer findings under-reported in Journals
Aug 22, 2005 - 9:44:00 PM, Reviewed by: Dr.

"We, as clinicians and researchers, have a tremendous responsibility to not only investigate and discover new agents, but also to disseminate our discoveries - good and bad - to the medical community at large, to ensure the safety and well-being of our patients."

 
Phase I cancer studies, trials that are conducted to determine the safety and maximum dose of a new agent, are under-reported in peer-reviewed journals - a trend that could ultimately delay scientific progress and negatively affect patient care, say researchers at The University of Texas M. D. Anderson Cancer Center in a new study out today (Mon., Aug, 22) online in Cancer.

Over the last decade, greater understanding of cancer at the molecular and cellular levels has resulted in a scientific discovery explosion, translating into the development of numerous potential anticancer agents. An excellent indication of this progress, says Luis Camacho, M.D., assistant professor of medicine in M. D. Anderson's Phase I Clinical Trials Program, is the 10-fold increase in the number of Investigational New Drug (IND) applications for oncology agents filed with the Food and Drug Administration - from 100 compounds in 1980 to over 1,000 in 1998.

"With all this new knowledge, the need to share information is paramount, now more than ever before," says Camacho, the study's senior author. "We, as clinicians and researchers, have a tremendous responsibility to not only investigate and discover new agents, but also to disseminate our discoveries - good and bad - to the medical community at large, to ensure the safety and well-being of our patients."

Given this acceleration of discovery, scientific meetings have become inundated with study submissions, reports Camacho. Yet, often these results are preliminary and subject to change after final analysis. Therefore, publishing in peer-reviewed scientific journals remains the "gold-standard" for sharing medical information, he says.

To understand the rate at which Phase I trials were being published, Camacho and his team analyzed the 275 Phase I abstracts accepted by the American Society of Clinical Oncology (ASCO) for presentation at its annual meeting in 1997, and determined whether those findings had been published over the next seven and a half years. Through repeated MEDLINE searches and emailed questionnaires, researchers discovered that by February 2001, two-thirds (67 percent) of the Phase I abstracts had been published in peer-reviewed medical journals.

Researchers found that the Phase I ASCO studies of novel (agents not approved by the FDA) and non-novel (studies including at least one FDA-approved agent) drugs were published at an equal rate. Research that was financially supported by the pharmaceutical industry was published at the same rate of those studies not industry-supported. There was no difference in the rate of oral and poster presentations published; however, oral presentations were published more quickly than those presented as posters.

Publishing positive or negative Phase I trial results is critically important in developing new, or modifying existing cancer therapies, Camacho says.

"Obviously, if a Phase I agent proves too toxic, we need to ensure that information is shared within the cancer medical community, so as to not put patients in harms way," Camacho says. "Of course, if Phase I studies are promising, publishing can encourage further investigation of these potential therapeutic agents."

In unique cases, Camacho says, positive Phase I results can have immediate impact on clinical care.

"Phase I studies are not necessarily first-in-human trials - they also can be combinations of already approved drugs," he adds. "If those combinations prove relatively non-toxic and show some effect, that combination can potentially be moved forward to Phase II and, in selected cases, used to treat patients, almost immediately."

The median time to publication - 3.4 years - also is very concerning, Camacho says. "Releasing data after such a lengthy interval may not allow researchers to build on their scientific experience, thereby significantly delaying further investigation with encouraging agents."

From the questionnaire sent to investigators, Camacho and his team learned that lack of time and investigator relocation were the major obstacles of publication. These reasons were unexpected, as researchers expected to learn that negative results, lack of interest in pursuing projects to completion, or the stringent peer-review process would be among the reasons why investigators had not published.

Given the investigators reasons for not publishing, Camacho says that academic institutions should provide academicians more time to concentrate on publishing efforts. In return, clinicians must be committed to reporting Phase I toxicities in peer-review literature.
 

- The study was funded, in part, by a Clinical Cancer Research Award from the Cancer and Leukemia Group B (CALGB), a cooperative cancer working group. Other authors on the study include Alexander Cheung, M.D., of M. D. Anderson; David R. Spriggs, M.D., and Jennifer Bacik, both of Memorial Sloan Kettering Cancer Center.
 

University of Texas M. D. Anderson Cancer Center

 
Subscribe to Ethics Newsletter
E-mail Address:

 



Related Ethics News
Regulating stem cell research
Overcoming Ethical Constraints
Drug tests on animals may be unreliable: study
Waiting For Trial Results Sometimes Unethical
NHGRI Funds Assessment of Public Attitudes About Population-Based Studies on Genes and Environment
Physicians More Likely To Disclose Medical Errors That Would Be Apparent To The Patient
Doctors inadvertently help terminally ill patients to die sooner
Intellectual property law and the protection of traditional knowledge
Conscientious objection in medicine should not be tolerated
Yale guidelines for physician interactions with pharmaceutical industry


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us